Novel Targets in Melanoma: Intralesional and Combination Therapy to Manipulate the Immune Response

Alicia A. Gingrich, Amanda R. Kirane

Research output: Contribution to journalReview articlepeer-review

Abstract

Clinical outcomes for metastatic melanoma have been dramatically altered by recent developments in immunotherapy and targeted strategies, but response to these therapies is not uniform, the majority of patients do not respond, and clinical response can be self-limited. Current directions in melanoma treatment aim to leverage a combination of therapies for tumors refractory to monoimmunotherapy, to include tumor-directed strategies, such as intralesional therapy and inhibitors designed for novel targets, which may augment current systemic agents when used in combination. Here, we summarize new classes of agents and emerging multimodal combination strategies that demonstrate significant promise in future melanoma management.

Original languageEnglish (US)
Pages (from-to)467-483
Number of pages17
JournalSurgical Oncology Clinics of North America
Volume29
Issue number3
DOIs
StatePublished - Jul 2020

Keywords

  • Checkpoint blockage
  • Combination therapy
  • Immunotherapy
  • Intralesional therapy
  • Metastatic melanoma

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Novel Targets in Melanoma: Intralesional and Combination Therapy to Manipulate the Immune Response'. Together they form a unique fingerprint.

Cite this